Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Stoke Therapeutics Q3 EPS $(0.65) Misses $(0.59) Estimate, Sales $10.632M Beat $5.511M Estimate

Author: Benzinga Newsdesk | November 04, 2025 04:02pm
Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.59) by 10.36 percent. This is a 38.3 percent decrease over losses of $(0.47) per share from the same period last year. The company reported quarterly sales of $10.632 million which beat the analyst consensus estimate of $5.511 million by 92.92 percent. This is a 117.25 percent increase over sales of $4.894 million the same period last year.

Posted In: STOK


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist